NONOF News and Press, Novo Nordisk - Class B From 03/03/26

2026-03-03 12:09:49 ET More on Novo Nordisk, Aspen Pharmacare Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks ...

2026-03-03 10:27:45 ET More on Hims & Hers Health, Novo Nordisk A/S Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript ...

2026-03-03 07:13:33 ET The Novo Nordisk ( NVO ) ( NONOF ) story keeps getting hammered by the markets. Every time it goes down by 10-20%, it seems the valuations have hit rock bottom, only for more downside to emerge. The latest round of selling has been in response to a REDEFIN...

2026-02-27 15:51:12 ET More on iShares MSCI Denmark Capped ETF, VanEck Indonesia Index ETF, etc. ARGT: 2026 Sets Up A Political Stability Trade ARGT: A Guide To Argentina Equity Exposure Via Global X's ETF Garden Of EDEN: Despite Turbulent Greenland Geopolitics, Denm...

2026-02-27 15:13:54 ET Novo Nordisk ( NVO ) has experienced a hefty sell-off following worse-than-expected trial results of their weight loss drug CagriSema. Simultaneously, their main competitor, Eli Lilly ( LLY ), managed to keep or even expand their edge.... Read the fu...

2026-02-27 06:33:45 ET The Tide Has Not Turned YET In my January 25, 2026 article , I argued that the tide may be turning for Novo Nordisk ( NVO ), the underdog relative to its archrival Eli Lilly ( LLY ) after the FDA approval of oral Wegovy. Since then, several eve...

2026-02-24 14:30:38 ET Intro I think everyone agrees that things have been genuinely tough for Hims & Hers Health, Inc. ( HIMS ), and its shareholders lately— the stock is down more than 75% after touching all‑time highs above $60 as recently as last October. I...

2026-02-24 12:50:19 ET More on Novo Nordisk A/S Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture Novo Nordisk: Redefine 4 Misses The Mark Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations Novo’s China obesi...

2026-02-24 09:00:00 ET Novo Nordisk A/S ( NVO ), listed in its home market as NOVO-B.CO, brought out a press release on February 23rd concerning results from its latest phase 3 trial for CagriSema. This is the company’s next-generation injectable weight loss drug, which c...

2026-02-24 08:47:21 ET Investment Thesis Hims & Hers Health ( HIMS ) has clearly moved from a valuation reset to a regulatory repricing event. HIMS over the past year has gone through a severe valuation reset, losing another 48% from my last coverage . However, the recen...